

Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children

NCT07297966

Status	RECRUITING
Phase	Phase 2
Sponsor	Min-Tze LIONG
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (5)

- Age < 6 years, gender not limited;
- Meets the clinical diagnostic criteria for recurrent respiratory tract infections (Clinical Diagnosis and Treatment Pathway for Recurrent Respiratory Tract Infections in Children (2022 Edition) 10);
- Parents or other legal guardians of the child fully understand the trial and voluntarily sign informed consent forms before the start of any research procedure;
- Willing to discontinue the use of other probiotics during the trial;
- Agree to the collection of fecal biological samples during this trial.

Exclusion (6)

- Those deemed by the investigator to have poor compliance or be unsuitable for participation;
- Allergic to the investigational product and its components;
- Allergic to respiratory tract infection drugs and their components;
- Respiratory infections caused by underlying diseases such as primary immunodeficiency diseases, acquired immunodeficiency syndrome (ADRS), congenital airway malformations, congenital heart disease, gastroesophageal reflux disease (GERD), and pulmonary dysplasia;
- Patients with severe malnutrition, rickets, and severe primary diseases of the heart, brain, liver, kidney, and hematopoietic systems;

... and 1 more (see full listing online)

Locations (2 total)

Xinyi City People's Hospital, Xingyi, Guangdong, China
Universiti Sains Malaysia, George Town, Pulau Pinang, Malaysia